The MAb AS1402, that binds to MUC1-N (the extra-cellular domain of the MUC1-complex) showed cellular toxicity in MUC1 positive breast cancer cells but failed to show efficacy in combination with letrazole compared to letrazole alone in a Phase III study among patients with metastatic breast cancer [18]. Here, MUC1 is linked to breast carcinoma.